

Investor Newsletter

Issue **01** 2016



MicroPort® Attends AsiaPCR 2016

Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended AsiaPCR 2016 held in Singapore. During the premier cardiovascular course that attracted over 2,000 cardiovascular professionals from 12 Asian countries including China, India, Malaysia, Japan and South Korea, MicroPort® displayed the excellent performance of its innovative stents and demonstrated its growth potentials, enabling more patients to know about and benefit from MicroPort® products.

On the first day of the conference, MicroPort® live broadcasted a PCI operation in which Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®") was used to cure left main bifurcation lesions. Conducted by Professor Shaoliang Chen and his team from Nanjing First Hospital, the operation showed that Firebird2® was successfully implanted into the occlusive coronary artery of a patient with severe coronary heart diseases. The excellent crossability of Firebird2® was spoken highly by Professor Chen as well as Asia PCR attendees.

Meanwhile, MicroPort® exhibited its cardiovascular devices and surgical management products in its booth, which attracted many interests and stimulated discussions of future business cooperation. Professor Runlin Gao of Fuwai Hospital visited MicroPort® booth and gave high praise to the prominent features of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), such as its outstanding crossability and low drug dosage. Vice President of MicroPort® International Business Linda Lin also took this opportunity to call on Professor KOH Tian-Hai from National Heart Centre Singapore, introducing to him Firehawk®'s design concepts and clinical researches, and exchanging opinions on Firehawk®'s market development prospect in Singapore.



MicroPort® Firesorb Bioresorbable Rapamycin Target Eluting Coronary Scaffold System Completes First Successful Implantation in the First FIM Clinical Trial

On January 18, the initiative meeting for "Evaluating the perspective and the single observation clinical trial for the safety and feasibility of applying MicroPort® Firesorb Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb") in First-in-Man("FIM") coronary heart disease treatment" was held in the interventional catheterization room of Fuwai Hospital of Chinese Academy of Medical Sciences.

Independently researched and developed by MicroPort®, Firesorb is the second generation of bioresorbable stent. The meeting was chaired by Professor Bo Xu, the director of the catheter room of Fuwai Hospital. The principal investigator Runlin Gao, Vice President Yuejin Yang, Director Shubin Qiao and more than 40 experts attended the meeting. MicroPort® Chief Marketing Officer Bo Peng, Chief Technology Officer Dr. Qiyi Luo, and Senior Vice President Yimin Xu, attended the meeting as well.

During the meeting, Professor Runlin Gao delivered a speech, introducing the unique features of Firesorb stent. He pointed out that the wall of Firesorb is thinner, which is expected to overcome the disadvantage of the first generation of bioresorbable stent. Dr. Qiyi Luo then introduced the performance of Firesorb. Professor Bo Xu explained the clinical trials and standard operating procedures in details, with particular emphasis on the optimized implantation technique of bioresorbable stent.

On January 19, Director Mengyue Yu from Fuwai Hospital selected the first receiver of the clinical trial and successfully implanted one Firesorb stent. Experts spoke highly of Firesorb's excellent crossability, support force, postoperative angiography, and IVUS and OCT angiographic effect.

Firesorb is currently the "first and only" polymer absorbable scaffold. Its wall thickness is only 100µm-125µm. Its design of thin wall allows fast endothelialization after scaffold implantation, which could reduce the risk of postoperative thrombosis. As less material is used to make the scaffold, the degradation period will be further shortened. In addition, the scaffold features targeting elution technique, which makes it the "first and only" absorbable scaffold with targeted release function. Bioresorbable Scaffold System only retains the drug on one surface that contacts blood vessels, reduces the dose of drug, enhances the efficiency of the treatment, and prevents a large amount of drug residual from remaining in the body for a long time. As Firesorb scaffold's first FIM clinical trials was launched, it will lay a good foundation for its following clinical trials.



Dongguan Kewei Disposable Arterial Micro Plug Filter Obtains EU **CE** Certification

Recently, the Disposable Arterial Micro Plug Filter, developed by Dongguan Kewei Medical Instrument Co ("Dongguan Kewei"), obtained the official CE Certification. This is Dongguan Kewei's first product that gained CE Certification, marking a milestone in Dongguan Kewei's globalization.

The Disposable Arterial Filter is a filtering device used to clean microemboli of blood after oxygenation. Arterial Filter is the last security barrier in Cardiac Surgery(Extracorporeal Circulation Operation), which can greatly reduce the risk of post-operative complications. Dongguan Kewei Disposable Arterial Filter features low pressure drop, excellent filtering ability, and clear vision of blood flow route. The product adopts a folding mesh screen design, which has large filtering area but small size. During surgery, blood flows into the filter tangently, which weakens the destructiveness to the blood. What's more, the product is equipped with an exhaust port on the top, which makes it easier to exhaust gas.

Before the CE Mark, Dongguan Kewei Disposable Arterial Micro Plug Filter has obtained China Food and Drug Administration ("CFDA") registration certificate, and has been widely used in cardiopulmonary bypass surgery. The product's safety and effectiveness are highly recognized by surgeons and patients, and has a relatively high market share. With the CE Certification, the filter will officially enter the EU market to benefit overseas patients.



MicroPort® Product Obtains **CFDA** Certification

Recently, independently researched and developed by MicroPort®, the Disposable Intravascular Catheter Accessories product obtained the official registration certificate issued by CFDA. This registration for the product is a combination of a registration renewal and product change. The Disposable Intravascular Catheter Accessories product is composed of a guidewire, high pressure valve and high pressure connecting pipe, which serves as the auxiliary equipment in angiography and interventional operations. Its clinical safety and effectiveness have been acknowledged by peers, surgeons, and patients.



MicroPort® Science and Technology Innovation Platform Wins the State Science and Technology Progress Award

On January 8, State Science and Technology Awards Ceremony was held in Beijing. The project of MicroPort®, "key technologies and industrialization platform of minimally invasive and implantable medical device", won the second prize of State Science and Technology Progress Award.

The State Science and Technology Progress Award is one of the 5 awards of the Award Science and Technology Awards, which was established under the State Council. State Council added "Enterprise Technical Innovation Engineering Category" into the categories of the State science and Technology Progress Award in 2008. This category became a key indicator of identifying the enterprise's innovation potential. Director Haifeng Liu from Shanghai Awards Office said, "MicroPort's 'key technologies and industrialization platform of minimally invasive and implantable medical device' project is very special. It is not awarded as a technology breakthrough or a new product through research and development, but as an overall innovation mode for an enterprise."

MicroPort®, ever since its establishment in 1998, has gone through a very extraordinary innovation process, and has explored a set of enterprise operation mode and innovation system. The system has proved its feasibility and effectiveness through this time's second prize of National Science and Technology Progress Prize. It is suitable for the industry characteristics--high-grade, precise and advanced, and is also suitable for the national conditions—greater, faster, better, more economical and accurate. As the first interventional medical devices research and development enterprise, MicroPort® created and led the development of domestic interventional medical device industry. It led the promotion and popularization of interventional therapy in the country, in addition to the development of intelligent manufacturing, biological materials, 3D printing technology and other cross disciplines. MicroPort®, applying the advanced business philosophy, has been integrating up to one hundred high-tech achievements into one system, has become a unique kind of its own, and thus has become the innovation leader in the field of medical science and Technology. It holds hundreds of high-end medical products in ten years. Chairman and CEO Dr. Zhaohua Chang said: "Through independent research, development and strategic acquisitions, MicroPort® has applied for 1710 patents around the world. Every 18 seconds or so, there is a product used to save life and improve the quality of life, or to directly help creating lives. This unique innovation model of MicroPort® obtains the recognition from National Supreme Science Award Association, and such award is no doubt a kind of motivation to the company. I believe this model will strongly improve MicroPort's continuous innovation capability, and will have a profound impact on the development of our company. "



MicroPort® Orthopedics National Logistic Platform and Distributors Training

From January 16 to January 18, MicroPort® Orthopedics launched a training course in Shanghai and Sichuan Province respectively. A total of 29 people attended the training, including staff from national logistic platform and distributors in Sichuan. Through various brain storms, lectures and hands-on proficiency tests, attendees are equipped with standard operation process, professional prosthesis knowledge and instrumentation management skill.

MicroPort® Orthopedics Attends the First National Symposium on Joint Replacement Perioperative Management and Quick Rehabilitation Project

From January 15 to January 17, MicroPort® Orthopedics attended the first National Symposium on Joint Replacement Perioperative Management and Quick Rehabilitation Project in Chengdu, Sichuan Province. The symposium was hosted by West China Hospital. Over 80 professionals were invited to deliver speeches. The symposium covered 11 topics including minimum invasive surgical technique, inter-operative hemorrhage management, pain management, joint functional recovery, fast-recovery process management and perioperative blood management. Over 800 attendees joined the symposium.



Investor Newsletter

Issue **01** 2016



For more information, please contact:

Hongbin Sun

Chief Financial Officer

Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)

Tel: (86)(21) 38954600

Email: ir@microport.com